Core Viewpoint - The strategic partnership between China Resources Pharmaceutical and Haohai Biological Technology marks a significant move into the medical aesthetics sector, leveraging each company's strengths to enhance market presence and product offerings [1][2][4]. Group 1: Partnership Details - The collaboration aims to establish a comprehensive "R&D-Production-Channel" cooperation system, integrating China Resources' extensive OTC network across 28 provincial regions with Haohai's industrial base advantages [1][2]. - Haohai Biological, recognized as one of the "three giants" in medical aesthetics, reported a gross margin of 77.47% for its medical aesthetic products last year, highlighting the profitability of this sector [1][4]. - The partnership is expected to facilitate Haohai's expansion into second- and third-tier markets, utilizing China Resources' established distribution channels [2][4]. Group 2: Market Context - The Chinese medical aesthetics market is projected to grow from 189.2 billion yuan in 2021 to 410.8 billion yuan by 2025, with a compound annual growth rate (CAGR) exceeding 17% [6][8]. - Non-surgical aesthetic procedures are anticipated to grow at a rate of over 15% annually, indicating a robust demand for these services [1][6]. - The entry of traditional pharmaceutical giants into the medical aesthetics space is accelerating, with companies like Sinopharm and Shanghai Pharmaceuticals expanding their presence through various strategies [6][8]. Group 3: Financial Implications - Haohai's revenue from medical aesthetics and wound care products is expected to reach 1.195 billion yuan in 2024, accounting for 44.38% of its total revenue, with hyaluronic acid products contributing 742 million yuan [3][4]. - The collaboration is anticipated to optimize cost structures, allowing Haohai to reduce its R&D expenses by 25.40% in the first quarter of 2025, as it will no longer need to invest heavily in building its own sales team [4][6]. Group 4: Industry Trends - The medical aesthetics industry is witnessing a shift towards brand consolidation and standardization, driven by stricter regulations and evolving consumer preferences [7][8]. - The consumer demographic is diversifying, with an increasing proportion of male and older consumers, leading to a broader range of aesthetic service offerings [7][8]. - The partnership between China Resources and Haohai is seen as a new model for upstream and downstream collaboration in the medical aesthetics industry, potentially driving the sector towards a more clustered and standardized future [7][8].

Group 1: Real Estate Sector Insights - The report emphasizes a short-term focus on stabilizing the real estate market, with expectations for new supportive policies such as mortgage rate cuts and increased housing supply [2][9] - The "Good House" policy is highlighted as a key driver for residential consumption and the transformation of real estate companies towards manufacturing [9][10] - The report identifies strong product capability and inventory management as critical factors for real estate companies to succeed in the evolving market [9][10] Group 2: Photovoltaic Industry Analysis - The photovoltaic sector is currently at multiple bottoms, with expectations for a rebound driven by price recovery and improved institutional holdings [3][11] - Recent government meetings have called for the regulation of low-price competition in the photovoltaic industry, indicating a shift towards supply-side reforms [11][12] - The report suggests that companies in the silicon material sector, such as Tongwei Co., Daqo New Energy, and GCL-Poly Energy, are likely to benefit the most from these reforms [11][12] Group 3: General Market Trends - The report notes that the overall market has seen fluctuations in major indices, with the Shanghai Composite Index closing at 3455 points, reflecting a slight decline of 0.09% [1] - Various industry performances are highlighted, with the fishing industry showing a significant increase of 12.06% in the last day, while the ground equipment sector experienced a notable decline of 5.38% [1]

Core Viewpoint - The article discusses innovative skincare solutions for postpartum mothers, highlighting non-invasive and safe water light treatments that cater to their specific skin concerns while allowing them to manage their time effectively [1][11]. Group 1: MESONUEVO - MESONUEVO offers a shallow water light treatment using EPM micro-needle transdermal technology, creating 0.05mm micro-channels in the stratum corneum without the need for anesthesia, enhancing nutrient absorption by over 10 times [1][3]. - The treatment is designed for comfort, with no pain during the procedure and a natural closure of channels within 6 hours, allowing mothers to apply makeup and continue daily activities [3]. - It is certified by the EU CE and ISO13485, featuring a "Youth Energy Essence" with over 40 natural active ingredients to address postpartum pigmentation and dullness [3]. Group 2: SEYO - SEYO utilizes TDA ultrasonic transdermal technology to deliver nutrients at a speed of 450 meters per second, reaching deep skin layers without needles, making it suitable for mothers seeking efficiency and safety [4][6]. - The treatment requires only 9 minutes and 35 seconds, allowing mothers to rejuvenate their skin during short breaks, such as while preparing formula for their babies [6]. - It is certified by the German Dermatology Association, ensuring that the essence is free from hormones and fragrances, making it safe for sensitive skin and breastfeeding mothers [6]. Group 3: DEP - DEP Superconductive Water Light employs a transdermal ion system to enhance skin permeability without invasiveness, recognized by the FDA as an "injection alternative" [7][9]. - The treatment is non-invasive, avoiding the discomfort associated with injections, and is clinically validated to deliver repair components effectively [9]. - It offers flexible solutions that can be combined with laser and radiofrequency treatments to address multiple postpartum skin issues [10]. Group 4: Jmoon - Jmoon is a pioneer in negative pressure transdermal water light technology, providing professional-grade results with home-use safety and convenience [11][13]. - The treatment opens skin channels using negative pressure and combines it with pulsed electric currents and nano-sized essence for deep penetration, achieving results comparable to professional treatments [13]. - It offers personalized care with three types of essences targeting common postpartum issues, all while being cost-effective and easy to use during baby’s nap time [13]. Conclusion - These four innovative water light technologies have reshaped the perception of medical beauty treatments, providing safe and effective solutions for postpartum skincare, allowing mothers to regain their confidence and skin health [1][11].

Market Overview - A-shares have resumed an upward trend after a period of consolidation, with the Shanghai Composite Index breaking through March highs and reaching new recent closing highs [1] - The market sentiment regarding trade conflicts has eased, and the geopolitical situation in the Middle East is viewed as a short-term emotional impact [1] - The low interest rate environment and rising risk appetite are supporting the A-share market's return to a slow upward trajectory [1] Sector Analysis - The innovation drug and banking sectors, which were previously popular, have resumed their upward trends after short-term adjustments [2] - The TMT and advanced manufacturing sectors are experiencing rebounds, indicating a high-low switch among sectors as the market remains event-driven [2] - Consumer expansion and domestic demand are key tasks for 2025, with expectations for policy support in sectors like dairy products, IP consumption, leisure tourism, and medical aesthetics [2] - The trend of robot localization and integration into daily life is expected to continue, with opportunities arising in sensors, controllers, and dexterous hands [2] - The semiconductor industry is moving towards localization, with a focus on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The military industry is anticipated to see a rebound in orders by 2025, with signs of recovery in various sub-sectors [2] - The innovation drug sector is expected to reach a turning point in fundamentals by 2025, following a period of adjustment [2] Trading Activity - A-shares experienced some intraday fluctuations but maintained an upward trend, with trading volume remaining stable and no signs of panic selling [3] - Leading sectors included pharmaceuticals, banking, non-ferrous metals, public utilities, and building materials, while sectors like computers, retail, communications, and power equipment saw declines [3]

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

| 昨日涨跌幅后五行业 | | --- | 2025 年 07 月 02 日 他 研 究 开源晨会 0702 ——晨会纪要 沪深300 及创业板指数近1年走势 数据来源：聚源 -16% 0% 16% 32% 48% 64% 2024-07 2024-11 2025-03 沪深300 创业板指 昨日涨跌幅前五行业 | 行业名称 | 涨跌幅(%) | | --- | --- | | 综合 | 2.601 | | 医药生物 | 1.804 | | 银行 | 1.535 | | 有色金属 | 1.489 | | 公用事业 | 1.046 | | 数据来源：聚源 | | | 行业名称 | 涨跌幅(%) | | --- | --- | | 计算机 | -1.182 | | 商贸零售 | -0.788 | | 通信 | -0.452 | | 传媒 | -0.376 | | 电力设备 | -0.373 | 数据来源：聚源 吴梦迪（分析师） wumengdi@kysec.cn 证书编号：S0790521070001 观点精粹 总量视角 【宏观经济】"两重"接力支撑 PMI，预计 Q2 GDP 约 5.2%——兼评 6 月 PM ...

Group 1: Innovation in Pharmaceuticals - The National Healthcare Security Administration and the National Health Commission have released measures to support the high-quality development of innovative drugs, including the use of healthcare data for drug research and development [1] - The policy encourages commercial health insurance companies to expand investment in innovative drugs and provide long-term funding support through investment funds [1] - The number of approved innovative drugs in China from January to May 2023 reached a five-year high, indicating significant breakthroughs in domestic drug research [1] - Major companies like 3SBio, CSPC Pharmaceutical Group, and Rongchang Bio have announced important international cooperation agreements, enhancing the global competitiveness of Chinese innovative drugs [1] - Several biotech companies, such as Innovent Biologics and Junshi Biosciences, are increasing R&D investments through equity financing, reflecting strong capital market support for innovative drug development [1] Group 2: Consumer Spending and Economic Policies - The "trade-in" policy has shown positive effects, with increased central government subsidies and an expanded range of products eligible for trade-in, potentially boosting consumer demand [2] - There is significant room for recovery in service consumption compared to goods consumption, suggesting future policies could target service sectors like tourism, dining, and entertainment [2] - Policies aimed at increasing pensions, promoting childcare subsidies, and improving social security can drive long-term consumer spending growth, particularly for key demographics [2] - Local governments can support specific consumption sectors through fiscal measures and targeted transfers, promoting regional consumption growth [2] Group 3: Commodity Market Insights - U.S. tariff policies may boost copper restocking demand, while China's stable domestic demand policies and potential Federal Reserve rate cuts could further drive copper prices up [3] - The demand for aluminum is expected to stabilize due to government efforts to support the real estate market and urban renewal projects, particularly in transportation and photovoltaic sectors [3] - Increased demand for gold in asset allocation, combined with an upcoming earnings realization period for gold stocks, may lead to a "Davis Double" effect in the gold sector [3] - China's export controls on strategic materials like tungsten and molybdenum, along with a 6% year-on-year reduction in tungsten mining quotas for 2025, are likely to support steady price increases for these materials [3] Group 4: Biotechnology and Investment - Jingbo Biotechnology's revenue is projected to grow from 233 million to 1.443 billion from 2021 to 2024, with net profit increasing from 57.39 million to 732 million, and net profit margin rising from 24.38% to 50.68% [5] - Yangshengtang, as a strategic investor, has injected 2 billion into Jingbo Biotechnology, with the investment linked to the strategic layout of Zhong Shanshan, founder of Nongfu Spring [5] - The collaboration with Yangshengtang provides Jingbo Biotechnology access to a vast retail network and consumer management experience, crucial for scaling production and expanding sales channels [5] - The partnership with Yangshengtang and Nongfu Spring enhances Jingbo Biotechnology's market competitiveness through improved consumer experience and brand management [5] - Yangshengtang's investment allows Jingbo Biotechnology to rapidly establish a presence in consumer goods, increasing market penetration, especially in marketing and product promotion [4]

Core Viewpoint - The strategic investment by Zhong Shanshan, the founder of Nongfu Spring, in Jinbo Biological represents a significant shift in the competitive landscape of the medical beauty industry in China, aiming to leverage the growing market for recombinant collagen products and enhance market presence through collaboration with established brands [1][36][37]. Group 1: Investment Details - Jinbo Biological announced a strategic partnership with Yangshengtang, raising 2 billion yuan through a private placement, marking a record for cash capital increases on the Beijing Stock Exchange [3][4]. - The investment will be used for developing a humanized collagen FAST database and product development, with 1.15 billion yuan allocated for this purpose and 850 million yuan for working capital [3]. - Following the announcement, Jinbo Biological's stock price surged, closing at 355.96 yuan per share, with a market capitalization of 40.96 billion yuan [6]. Group 2: Company Backgrounds - Zhong Shanshan, aged 71, is a legendary entrepreneur who founded Nongfu Spring and Yangshengtang, creating a business empire valued over 400 billion yuan [11]. - Yang Xia, the 51-year-old founder of Jinbo Biological, transitioned from academia to entrepreneurship, focusing on synthetic collagen for medical applications after identifying challenges in organ preservation [12][13]. Group 3: Market Potential - The recombinant collagen product market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 and exceeding 219.38 billion yuan by 2030 [25][26]. - Jinbo Biological's revenue is expected to reach 1.443 billion yuan in 2024, reflecting an 84.92% year-on-year increase, with a net profit of 732 million yuan, up 144.27% [18]. Group 4: Strategic Synergies - The partnership is expected to enhance Yangshengtang's product line with high-end collagen ingredients, while Jinbo Biological can leverage Yangshengtang's extensive retail network of over 300,000 outlets to penetrate the consumer market [29][36]. - The collaboration aims to transform Jinbo Biological from a technology leader to a market leader, with the anticipated launch of new products in the third quarter [31]. Group 5: Competitive Landscape - The medical beauty industry is highly competitive, with Jinbo Biological facing challenges from established players like Huaxi Biological and Aimeike, which are also expanding into recombinant collagen [34]. - Jinbo Biological's dynamic price-to-earnings ratio of over 50 requires sustained high growth to maintain investor confidence, especially as sales expenses are projected to rise significantly [34][35].

Core Viewpoint - The article discusses the significant investment by Zhong Shanshan in Jinbo Biological, a company specializing in recombinant collagen products, highlighting the potential for growth in the medical beauty industry and the strategic collaboration between the two entities [4][6][12]. Group 1: Investment Details - Jinbo Biological announced two transactions, including introducing Yangshengtang as a strategic investor, with a total transaction amount reaching 3.4 billion yuan [5][8]. - The strategic investment involves issuing up to 7.1757 million shares, representing 6.24% of the pre-issue total share capital, aiming to raise no more than 2 billion yuan [8]. - Yang Xia, the founder of Jinbo Biological, transferred 5.7533 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [9][10]. Group 2: Company Background - Jinbo Biological, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [6][18]. - The company has developed a range of products, including recombinant type III collagen, which has been widely adopted in medical and cosmetic applications [22][23]. - Jinbo Biological's revenue for 2024 is projected to be 1.443 billion yuan, reflecting a year-on-year growth of 84.92%, with a net profit of 732 million yuan, marking an increase of over 140% [23]. Group 3: Market Dynamics - The medical beauty industry, particularly the recombinant collagen segment, is experiencing rapid growth, with high consumer interest and significant market potential [26][30]. - The article notes that the pursuit of beauty is a strong driver for repeat purchases, making this sector highly lucrative [30]. - Jinbo Biological's products have gained popularity, with its core product, the injectable recombinant type III collagen, being used in over 4,000 medical institutions [23][24].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Views - The report highlights the strong performance of high-end brands and emerging effective brands in the beauty and medical aesthetics sectors, particularly during the 618 shopping festival, which saw a total e-commerce sales of 8,556 billion yuan, a year-on-year increase of 15.2% [8][36] - The medical aesthetics market is expected to grow significantly with the approval of new products, such as the first compliant lipolytic injection in China, which is projected to expand the market from 135 million yuan in 2023 to 805 million yuan by 2025 [31][32] Summary by Sections Market Review - The beauty care index rose by 2.55% in May 2025, ranking 14th among all primary industries, underperforming the overall market [16] - In May, the top performers in the medical aesthetics sector included Kedi-B (+61.3%), Sihuan Pharmaceutical (+36.1%), and East China Pharmaceutical (+15.1%) [21][26] - In the cosmetics sector, the leading companies were Lafang Jiahua (+28.0%), Shuiyang Co. (+24.5%), and Babi Co. (+19.1%) [27][29] Medical Aesthetics - The approval of Mai Nuo Wei's "Xian Su" injection marks a significant breakthrough in the domestic lipolytic market, with a projected market size increase to 8.05 billion yuan by 2025 [31][32] - The exit of CPE as a major shareholder in Meili Tianyuan is expected to optimize the company's governance structure and enhance its market position [32] Cosmetics - The 618 shopping festival saw a total GMV of 659.09 billion yuan in the beauty category, with international high-end brands showing resilience and growth due to strong brand effects [8][41] - Domestic brands like Pechoin and Han Shu led the sales on platforms like Tmall and Douyin, with significant growth rates for new brands [44] Investment Recommendations - The report recommends focusing on strong domestic beauty brands and those benefiting from high-growth segments, highlighting companies like Shangmei Co., Maogeping, and Pechoin as key investment opportunities [47][48] - In the medical aesthetics sector, companies like Aimeike and Kedi-B are recommended for their potential growth driven by new product launches and market expansion [47][48] Market Trends - The report notes a shift towards "emotional consumption" in the beauty sector, with consumers increasingly seeking products that offer aesthetic and therapeutic benefits [48] - The overall market is expected to continue evolving with new product introductions and innovative marketing strategies as the industry enters a seasonal transition [49]